Tag: biologics

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of US Personalized Medicine Market size & share revenue was valued at approximately USD 56.37 Billion in 2024 and is expected to reach USD 66.13 Billion in 2025 and is expected to reach around USD 252.93 Billion by 2034, at a CAGR of 17.32% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Illumina Inc., Precision Biologics, Danaher Corporation (Cepheid Inc.), GE HealthCare, Celera Diagnostics LLC, Decode Genetics Inc., Exact Sciences Corporation, IBM Corporation, Exagen Inc., Biogen, QIAGEN, Genentech Inc., 23andMe Inc., Asuragen Inc and others.

LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2025.

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (NASDAQ:NEOG), Alto Neuroscience, Inc. (NYSE:ANRO), RxSight, Inc. (NASDAQ:RXST), and Replimune Group, Inc. (NASDAQ:REPL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”), of the important September 15, 2025 lead plaintiff deadline.

– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) –